Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial

BackgroundPsoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that dietary interventions may also play a role in managing inflammation associated with this condition. The Mediterranean diet (MedDiet)...

Full description

Saved in:
Bibliographic Details
Main Authors: Javier Perez-Bootello, Emilio Berna-Rico, Carlota Abbad-Jaime de Aragon, Ruth Cova-Martin, Leticia Goni, Asuncion Ballester-Martinez, Pedro Jaen-Olasolo, Nehal Mehta, Joel M Gelfand, Miguel Angel Martinez-Gonzalez, Alvaro Gonzalez-Cantero
Format: Article
Language:English
Published: JMIR Publications 2025-01-01
Series:JMIR Research Protocols
Online Access:https://www.researchprotocols.org/2025/1/e64277
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832582450227707904
author Javier Perez-Bootello
Emilio Berna-Rico
Carlota Abbad-Jaime de Aragon
Ruth Cova-Martin
Leticia Goni
Asuncion Ballester-Martinez
Pedro Jaen-Olasolo
Nehal Mehta
Joel M Gelfand
Miguel Angel Martinez-Gonzalez
Alvaro Gonzalez-Cantero
author_facet Javier Perez-Bootello
Emilio Berna-Rico
Carlota Abbad-Jaime de Aragon
Ruth Cova-Martin
Leticia Goni
Asuncion Ballester-Martinez
Pedro Jaen-Olasolo
Nehal Mehta
Joel M Gelfand
Miguel Angel Martinez-Gonzalez
Alvaro Gonzalez-Cantero
author_sort Javier Perez-Bootello
collection DOAJ
description BackgroundPsoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that dietary interventions may also play a role in managing inflammation associated with this condition. The Mediterranean diet (MedDiet), prevalent in southern European countries, has been widely recognized for its ability to reduce cardiovascular mortality, largely due to its anti-inflammatory properties. This anti-inflammatory potential has prompted interest in exploring the MedDiet’s role in immune-mediated diseases, including psoriasis. Observational studies have indicated potential benefits, such as reductions in the Psoriasis Area and Severity Index. However, there is a need for well-designed clinical trials to address the methodological limitations of these studies and to establish specific dietary recommendations for psoriasis. ObjectiveThis study aims to evaluate the impact of an intensive dietary intervention based on the MedDiet in patients with psoriasis. The study will assess the effects of this intervention on skin involvement, metabolic parameters, and inflammatory cytokines. In addition, the emotional well-being and quality of life of participants will be evaluated using validated questionnaires. A methodological analysis will also be conducted to enhance the design of future large-scale clinical trials. MethodsAn open-label, single-blinded (evaluator) randomized controlled trial was designed to assess the impact of a high-intensity MedDiet intervention in patients with mild-to-moderate psoriasis. A total of 38 patients will be randomly assigned into 2 groups—an intervention group receiving the MedDiet intervention and a control group receiving standard care. The intervention group will participate in dietary education sessions aimed at adopting the MedDiet over 4 months, with monthly monitoring by experienced nutritionists. Participants will receive 500 mL of extra virgin olive oil per week, along with informative materials, recipes, and weekly menus. In contrast, the control group will receive standard low-fat diet recommendations without nutritionist monitoring. All participants will undergo a baseline visit, a 2-month follow-up visit, and a final visit at 4 months. Blood tests will be conducted at the beginning and end of the study. This study protocol was approved by the Institutional Review Board of the Hospital Ramón y Cajal (Madrid) in July 2023. ResultsEnrollment concluded in October 2024, with data collection set to finish by February 2025. The findings will be presented at national and international conferences and published in peer-reviewed journals. ConclusionsThis protocol outlines the design of a clinical trial that implements the MedDiet in patients with psoriasis to evaluate its benefits on skin involvement, systemic inflammation, and quality of life. Trial RegistrationClinicalTrials.gov NCT06257641; https://clinicaltrials.gov/study/NCT06257641 International Registered Report Identifier (IRRID)DERR1-10.2196/64277
format Article
id doaj-art-67a17902144e4280859f428afa69b9de
institution Kabale University
issn 1929-0748
language English
publishDate 2025-01-01
publisher JMIR Publications
record_format Article
series JMIR Research Protocols
spelling doaj-art-67a17902144e4280859f428afa69b9de2025-01-29T19:30:30ZengJMIR PublicationsJMIR Research Protocols1929-07482025-01-0114e6427710.2196/64277Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled TrialJavier Perez-Bootellohttps://orcid.org/0009-0009-2253-5587Emilio Berna-Ricohttps://orcid.org/0000-0003-0348-5421Carlota Abbad-Jaime de Aragonhttps://orcid.org/0000-0002-5587-1204Ruth Cova-Martinhttps://orcid.org/0009-0001-3348-4967Leticia Gonihttps://orcid.org/0000-0002-5479-2045Asuncion Ballester-Martinezhttps://orcid.org/0000-0002-6780-0390Pedro Jaen-Olasolohttps://orcid.org/0000-0002-7334-0044Nehal Mehtahttps://orcid.org/0000-0003-4939-5130Joel M Gelfandhttps://orcid.org/0000-0003-3480-2661Miguel Angel Martinez-Gonzalezhttps://orcid.org/0000-0002-3917-9808Alvaro Gonzalez-Canterohttps://orcid.org/0000-0001-8060-4784 BackgroundPsoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that dietary interventions may also play a role in managing inflammation associated with this condition. The Mediterranean diet (MedDiet), prevalent in southern European countries, has been widely recognized for its ability to reduce cardiovascular mortality, largely due to its anti-inflammatory properties. This anti-inflammatory potential has prompted interest in exploring the MedDiet’s role in immune-mediated diseases, including psoriasis. Observational studies have indicated potential benefits, such as reductions in the Psoriasis Area and Severity Index. However, there is a need for well-designed clinical trials to address the methodological limitations of these studies and to establish specific dietary recommendations for psoriasis. ObjectiveThis study aims to evaluate the impact of an intensive dietary intervention based on the MedDiet in patients with psoriasis. The study will assess the effects of this intervention on skin involvement, metabolic parameters, and inflammatory cytokines. In addition, the emotional well-being and quality of life of participants will be evaluated using validated questionnaires. A methodological analysis will also be conducted to enhance the design of future large-scale clinical trials. MethodsAn open-label, single-blinded (evaluator) randomized controlled trial was designed to assess the impact of a high-intensity MedDiet intervention in patients with mild-to-moderate psoriasis. A total of 38 patients will be randomly assigned into 2 groups—an intervention group receiving the MedDiet intervention and a control group receiving standard care. The intervention group will participate in dietary education sessions aimed at adopting the MedDiet over 4 months, with monthly monitoring by experienced nutritionists. Participants will receive 500 mL of extra virgin olive oil per week, along with informative materials, recipes, and weekly menus. In contrast, the control group will receive standard low-fat diet recommendations without nutritionist monitoring. All participants will undergo a baseline visit, a 2-month follow-up visit, and a final visit at 4 months. Blood tests will be conducted at the beginning and end of the study. This study protocol was approved by the Institutional Review Board of the Hospital Ramón y Cajal (Madrid) in July 2023. ResultsEnrollment concluded in October 2024, with data collection set to finish by February 2025. The findings will be presented at national and international conferences and published in peer-reviewed journals. ConclusionsThis protocol outlines the design of a clinical trial that implements the MedDiet in patients with psoriasis to evaluate its benefits on skin involvement, systemic inflammation, and quality of life. Trial RegistrationClinicalTrials.gov NCT06257641; https://clinicaltrials.gov/study/NCT06257641 International Registered Report Identifier (IRRID)DERR1-10.2196/64277https://www.researchprotocols.org/2025/1/e64277
spellingShingle Javier Perez-Bootello
Emilio Berna-Rico
Carlota Abbad-Jaime de Aragon
Ruth Cova-Martin
Leticia Goni
Asuncion Ballester-Martinez
Pedro Jaen-Olasolo
Nehal Mehta
Joel M Gelfand
Miguel Angel Martinez-Gonzalez
Alvaro Gonzalez-Cantero
Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
JMIR Research Protocols
title Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
title_full Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
title_fullStr Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
title_full_unstemmed Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
title_short Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial
title_sort impact of the mediterranean diet on patients with psoriasis protocol for a randomized controlled trial
url https://www.researchprotocols.org/2025/1/e64277
work_keys_str_mv AT javierperezbootello impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT emiliobernarico impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT carlotaabbadjaimedearagon impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT ruthcovamartin impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT leticiagoni impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT asuncionballestermartinez impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT pedrojaenolasolo impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT nehalmehta impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT joelmgelfand impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT miguelangelmartinezgonzalez impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial
AT alvarogonzalezcantero impactofthemediterraneandietonpatientswithpsoriasisprotocolforarandomizedcontrolledtrial